Todd Girolamo Sells Shares of ProKidney Corp. $PROK
Key Points
- Todd Girolamo sold 163,857 shares of ProKidney Corp. ($PROK).
- $PROK last traded around $1.67.
Todd Girolamo, Chief Legal Officer at ProKidney Corp. ($PROK), sold 163,857 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
ProKidney Corp. ($PROK) Stock
ProKidney Corp. Earnings
Analysts Set New Price Targets
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.